Key result
Nitric oxide donors inhibit hormone- and forskolin-stimulated type VI adenylyl cyclase activity in N18TG2 neuroblastoma cells by decreasing the Vmax of the enzyme via S-nitrosylation.
Nitric oxide acts as a novel cellular regulator of the type VI isoform of adenylyl cyclase via S-nitrosylation.
No immediate clinical implications; leaves open isoform-specific NO regulation of adenylyl cyclase in cardiovascular tissues.
Nitric oxide (NO) donors inhibit hormone- and forskolin-stimulated adenylyl cyclase activity in purified plasma membrane preparations from N18TG2 neuroblastoma cells. Northern blot analyses indicate that the predominant isoform of adenylyl cyclase in N18TG2 cells is the type VI. Our experiments eliminate all the known regulatory proteins for this isoform as possible targets of NO. NO decreases the Vmax of the enzyme without altering the Km for ATP. Occupancy of the substrate-binding site protects the enzyme from the inhibitory effects of NO, suggesting that the conformation of the enzyme determines its sensitivity. The inhibition is reversed by reducing agents, implicating a Cys residue(s) as the target for nitric oxide and an S-nitrosylation as the underlying modification. These findings implicate NO as a novel cellular regulator of the type VI isoform of adenylyl cyclase.
No takes yet. Share an insight, caveat, or question.
McVey et al. (1999) studied this question. Nitric oxide (NO) donors was evaluated on Adenylyl cyclase activity. Nitric oxide donors inhibit hormone- and forskolin-stimulated type VI adenylyl cyclase activity in N18TG2 neuroblastoma cells by decreasing the Vmax of the enzyme via S-nitrosylation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: